Chemours Lowers Outlook for 2023

1 Mins read

Chemours, a leading provider of performance chemicals, has revised its outlook for 2023 following a decline in its third-quarter results. The company now forecasts adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in the range of $1.03 billion to $1.08 billion, compared to its previous outlook of $1.1 billion to $1.18 billion.

The adjusted free cash flow for the year is expected to exceed $225 million, factoring in approximately $400 million of capital expenditures. This is a reduction from the previous guidance of free cash flow surpassing $325 million, which included the same amount of capital expenditures.

The revision in guidance comes as Chemours experienced a decline in sales and a significant drop in net income during the third quarter.

Mark Newman, Chief Executive of Chemours, attributed these quarterly results to the weaker global macroeconomic environment. He highlighted that the impact was primarily felt in the company’s titanium technologies segment and advanced materials portfolio within the advanced performance materials segment.

Overall, Chemours is reallocating its forecasts for 2023 to reflect the challenges faced in the current economic climate.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

92 − = 91